you are viewing a single comment's thread.
Short SRPT not VRNG. Leave us longs be Srpt should be at 1.5 on the high side.
Believe it or not, SRPT will most likely double in the f=very near future with future updates on their drug that had amazing results thus far, based on a six minute walk test for muscle dystrophy
They tested it on just ten people and for all we know they could be kin to members of the jury in this case and we all know how smart they were to base results on. Anyway I was just comparing the two companies from the speculation standpoint.
Then you just answered your own question knucklehead!
If you are looking at pharmas look at IMUC, CUR, and EXEL (which has a catalyst Nov. 29)
ARNA, already approved, awaiting DEA ranking